#### Palliative Care Integration In Hematology

Thomas W. LeBlanc, MD, MA, MHS, FAAHPM, FASCO Associate Professor of Medicine with Tenure Division of Hematologic Malignancies

Director, Cancer Patient Experience Research Program (CPEP)









### DOES JEAN NEED PALLIATIVE CARE?

3



## WHAT ARE THE PALLIATIVE AND END-OF-LIFE CARE NEEDS OF HEMATOLOGY PATIENTS?



# 54%



# 810/0

# 39%



# 43%
















# 40,610

#### **Unmet End-of-Life Needs in Hematologic Malignancies**



Hui, et al. Cancer 2014

#### **Outcomes: The "Quality Measures" Gap**

- Patients with blood cancers are more likely to: 1,2
  - receive chemotherapy in the last 14 days of life
  - spend time in an ICU in the last 30 days of life
- Patients with blood cancers are less likely to:
  - access consultative palliative care services<sup>3</sup>
  - use hospice services<sup>4</sup>
    - Or, are more likely to die within 7 days of enrollment, or within 24 hrs of enrollment <sup>5</sup>
    - Median LOS of 11 days, vs. 19 for solid tumors <sup>5</sup>

1. Howell, DA, et al. "Destined to die in hospital? Systematic review and meta-analysis of place of death in haematological malignancy." BMC Pall Care, 2010.

2. Hui, et al. "Quality of end-of-life care in patients with hematologic malignancies: a retrospective cohort study." Cancer 2014


3. Howell DA, et al. Haematological malignancy: are patients appropriately referred for specialist palliative and hospice care? A systematic review and meta-analysis of published data." *Palliat Med* 2011.

4. Odejide, et al. "Hospice use among patients with lymphoma: impact of disease aggressiveness and curability." JNCI, 2015.

5. LeBlanc TW, Abernethy AP, Casarett DJ. "What Is Different About Patients With Hematologic Malignancies? A Retrospective Cohort Study of Cancer Patients Referred to a Hospice Research Network." Journal of Pain and Symptom Management, 2014

#### **Duke** Cancer Institute


#### **Burden of Care in AML**



- ICU admissions = 31.7%
- Median hospitalizations = 4.2 Palliative care consult = 16.2%
  - Hospice utilization = 22%


El-Jawahri, Cancer 2015

#### **Unmet Symptom Needs in Hematologic Malignancies**



Manitta V, et al. "The symptom burden of patients with hematological malignancy: a cross-sectional observational study." JPSM 2011.

#### **Symptom Burden**







#### What the literature tells us...

- 1. Unique barriers to EOL care
- 2. Clinicians are different
- 3. Hospice doesn't work well in hematology

#### **#1 – Blood Cancers are Different**

Remarkable prognostic heterogeneity (uncertainty)

- Some entirely curable with chemotherapy
- Others more like chronic, indolent diseases;
  - More likely to die of something else

Some confer a dismal prognosis, yet cure remains possible

- When curative-intent treatments do not work, much misery may result
  - Sometimes almost kill to cure

#### **#1 – Unique Barriers to EOL Care**

Identifying the end-of-life phase is more difficult<sup>1</sup>

Survey data on heme docs perspectives about barriers to EOL care:<sup>2</sup>

- Unrealistic patient expectations (97.3%)
- Clinician concern about taking away hope (71.3%)
- Unrealistic clinician expectations (59%)

2. Odejide O, et al. "Barriers to quality end-of-life care for patients with blood cancers." JCO, 2016

<sup>1.</sup> Odejide O, et al. "End-of-life care for patients with blood cancers: a series of focus groups with hematologic oncologists." JOP 2014



#### **Illness Understanding – AML**




Figure 3. Patients' and oncologists' perceptions of the likelihood of cure of leukemia.

El-Jawahri, The Oncologist, 2018

#### U Duke Cancer Institute

#### **Illness Understanding – AML**




Figure 4. Patients' and oncologists' perceptions of the likelihood of cure. (A): Perceptions among those receiving intensive chemotherapy. (B): Perceptions among those receiving nonintensive chemotherapy.

#### El-Jawahri, The Oncologist, 2018



#### **Illness Understanding – AML**




Figure 2. Patients' and oncologists' perceptions of the risk of treatment-related mortality. Abbreviation: TRM, treatment-related mortality.

El-Jawahri, The Oncologist, 2018

#### **#2 – The Doctors are Different**

Survey of 120 hematologic and 120 solid tumor oncologists at MD Anderson Cancer Center (Texas)

Hematologic malignancy specialists are more likely to:

- Favor systemic therapy with moderate toxicity and no survival benefit
- Have a sense of failure with dz progression

...And are less comfortable discussing:

- death and dying
- Hospice referral

#### **#2 – The Doctors are Different**

3 tertiary centers w/ established PC programs

- Surveys and semi-structured interviews to better understand barriers to PC referral
- 66 interviewees; 23 heme, 43 solid tumor

Most blood cancer specialists viewed palliative care as just end-of-life care, or hospice

Frequent concerns about philosophical issues:

• non-palliative goals, not wanting another clinician to intrude on the patient-doctor relationship, etc.

LeBlanc TW, et al. "Perceptions of palliative care among hematologic malignancy specialists: a mixed-methods study." Journal of Oncology Practice, 2015.

#### **#3 – Hospice Care and Transfusions**

National survey study of 349 hematologic oncologists

Key messages:

- Hospice care is helpful overall (68.1%)
- Home hospice care is inadequate for blood cancer patients' needs (46%)

>50% said they would be more likely to refer patients to hospice if transfusions were more available

Odejide O, et al. Cancer, 2017.

#### U Duke Cancer Institute

#### **Hospice Use in Leukemias**




Figure 2. Trends in transfusion dependence and hospice use. The panels illustrate proportions of patients who were transfusion dependent at the time of death (A), who were enrolled in hospice at the time of death (B), and in median duration of hospice stay (C). The P values and CIs were calculated from generalized linear regression A-B) or quantile regression (C).

LeBlanc, TW et al. Blood 2018

#### U Duke Cancer Institute

#### **EOL Quality Measures in Leukemias**




Figure 3. Indicators of EOL care quality among Medicare beneficiaries with leukemia, stratified by transfusion dependence and use of hospice at the end of life. (A) Proportions of patients dying in the inpatient setting, with an ICU admission in the last 30 days of life, or with chemotherapy administration in the last 14 days of life. (B) Median Medicare spending in the last 30 days of life (error bars indicate IQR).

LeBlanc, TW et al. Blood 2018



### DOES PALLIATIVE CARE WORK IN HEMATOLOGY?

#### **Duke** Cancer Institute




Figure 2. Elements of palliative care (PC) vs oncologic care visits at clinical turning points. EOL indicates end of life.

Yoong JAMA IM 17(34) 2013

#### **Integrated Palliative Care Studies in Oncology**

Many randomized clinical trials:

- Bakitas et al, JAMA 2009, ENABLE II study
- Temel et al, NEJM 2010
- Zimmerman et al, Lancet 2014
- Bakitas et al, JCO 2015, ENABLE III study
- Grudzen et al, JAMA Oncology 2016
- Temel et al, JCO 2016
- El-Jawahri et al, JAMA 2016, SHIELD study
- Vanbutsele et al, Lancet Onc 2018
- El-Jawahri and LeBlanc, JAMA Onc 2020, LEAP trial

Many patient-centered outcome improvements

- Starting to see long-term and caregiver outcomes improve

No study has shown harm

#### 🔰 **Duke** Cancer Institute

#### Improved outcomes in these studies

- Quality of life
- Symptom management
- Mood/depression
- Prognostic understanding
- Caregiver outcomes
- Utilization/costs
- Satisfaction
- End-of-life outcomes
- Survival

#### **Professional Society Recommendations**

- American Society of Clinical Oncology
  - "any patient with metastatic cancer and/or high symptom burden"
- American College of Surgeons, Commission on Cancer
  - Accredited programs "required to offer palliative care either on site or by referral"
- National Comprehensive Cancer Network
  - "Institutions should develop processes for integrating palliative care into cancer care, both as part of usual oncology care and for patients with specialty palliative care needs"
- Oncology Nursing Society
  - "All patients with cancer benefit from palliative care"
  - "Palliative care should begin at time of diagnosis"

Smith TJ, et al. "American Society of Clinical Oncology Provisional Clinical Opinion: the Integration of Palliative Care Into Standard Oncology Care." *Journal of Clinical Oncology*, 2012. American College of Surgeons New CoC Accreditation Standards, 2011: <a href="https://www.facs.org/media/press-releases/2011/coc-standards0811">https://www.facs.org/media/press-releases/2011/coc-standards0811</a> NCCN Guidelines Version 2.2015 – Palliative Care: <a href="http://www.nccn.org/professionals/physician\_gls/PDF/palliative.pdf">https://www.facs.org/media/press-releases/2011/coc-standards0811</a> ONS Position Statement: Palliative Care for People With Cancer: <a href="https://www.ons.org/advocacy-policy/positions/practice/palliative-care">https://www.ons.org/advocacy-policy/positions/practice/palliative-care</a>

#### Randomized Trial of Inpatient Palliative Care Intervention for Patients Hospitalized for Hematopoietic Stem Cell Transplantation (HCT)

Areej El-Jawahri, Thomas LeBlanc, Harry VanDusen, Lara Traeger, Joseph Greer, William Pirl, Vicki Jackson, Jason Telles, Alison Rhodes, Thomas Spitzer, Steven McAfee, Yi-Bin Chen, Stephanie Lee, Jennifer Temel





PRESENTED AT: **PALLIATIVE CARE IN ONCOLOGY SYMPOSIUM** Slides are the property of the author. Permission required for reuse.



### **Study Design**

160 patients with hematologic malignancies within 72 hour of admission for HCT (and their willing family caregivers)



D


#### Inpatient Integrated Palliative and Transplant Care -At least 2 visits weekly during HCT hospitalization.

Transplant Care Alone
Palliative care consult upon request.

Longitudinal data collection - Week 2 (primary) - Three & six months post HCT

PRESENTED AT: PALLIATIVE CARE IN ONCOLOGY SYMPOSIUM

Slides are the property of the author. Permission required for reuse.




PRESENTED AT: **PALLIATIVE CARE IN ONCOLOGY SYMPOSIUM** Slides are the property of the author. Permission required for reuse.



### Patient QOL




#### Δ FACT-BMT: -14.7 vs. -21.5 **P = 0.04**, Cohen's d = 2.9





# **Patient Symptom Burden**

#### Δ ESAS: 17.3 vs. 23.1 **P = 0.03**, Cohen's d = 0.4





COR



## CORe

### **Patient Mood**





#### Δ HADS-D: 2.4 vs. 3.9, **P = 0.02**, Cohen's d = 0.4

#### Δ HADS-A: -0.8 vs. 1.1 **P = 0.0006**, Cohen's d = 0.6



# Week-2 Outcomes

CORe

Week-2 Outcomes	Adjusted mean difference	95% CI	P-Value
FACT – BMT (primary outcome)	7.73	1.27 to 14.19	0.019
FACT – Fatigue	3.88	0.21 to 7.54	0.038
ESAS – Symptom burden	-6.26	-11.46 to -1.05	0.019
HADS – Depression symptoms	-1.74	-3.01 to -0.47	0.008
HADS – Anxiety symptoms	-2.26	-3.22 to -1.29	<0.001
PHQ-9 – Depression	-1.28	-2.82 to 0.27	0.104





# **3 Month Outcomes**


CORe

3 Month Outcomes	Adjusted mean difference	95%CI	P-Value
FACT – BMT	5.34	0.04 to 10.65	0.048
FACT – Fatigue	2.00	-1.08 to 5.09	0.202
ESAS – Symptom burden	-2.44	-6.29 to 1.41	0.212
HADS – Depression symptoms	-1.70	-2.75 to -0.65	0.002
HADS – Anxiety symptoms	-0.76	-1.73 to 0.23	0.130
PHQ-9 – Depression	-2.12	-3.42 to -0.814	0.002
PCL – PTSD symptoms	-4.35	-7.12 to -1.58	0.002

### **6-Month Outcomes**

6 Month Outcomes	Adjusted Mean Difference	95% CI	P- Value
FACT – BMT	2.72	-2.96 to 8.39	0.346
FACT – Fatigue	0.10	-3.38 to 3.58	.957
HADS – Depression	-1.21	-2.26 to -0.16	0.024
HADS – Anxiety symptoms	-0.61	-1.69 to 0.47	0.267
PHQ-9 – Depression	-1.63	-3.08 to -0.19	0.027
PCL – PTSD Symptoms	-4.02	-7.18 to -0.86	0.013

### **Psychological Distress at 6-Months**




### **Caregiver Outcomes**


2-week Caregiver Outcomes	Adjusted mean difference	95% CI	P-value
HADS-Depression	-1.65	-3.01 to -0.29	0.018
HADS-Anxiety	-0.14	-1.56 to 1.27	0.84
QOL	3.38	-1.59 to 8.35	0.180

#### Improvement in two domains of QOL

- Coping: adjusted mean difference = 1.01, P = 0.009
- Administrative/finances: adjusted mean difference = 0.67, P = 0.029



El-Jawahri JAMA 316(20) 2016



#### El-Jawahri JAMA 316(20) 2016





### Multi-Site Randomized Trial of Integrated Palliative and Oncology Care for Patients with Acute Myeloid Leukemia (AML)

Areej El-Jawahri MD, Thomas W. LeBlanc MD, Alison Kavanaugh NP, Jason A. Webb MD, Vicki A. Jackson MD, Toby Campbell MD, Nina O'Connor MD, Selina Luger MD, Ellin Gafford MD, Jillian Gustin MD, Bhavana Bhatnagar MD, Amir Fathi MD, Gabriela Hobbs MD, Julie Foster NP, Showly Nicholson BS, Debra Davis RN BSN, Hilena Addis BS, Dagny Vaughn BA, Nora Horick MS, Joseph A. Greer PhD, Jennifer S. Temel MD


Areej El-Jawahri MD

PRESENTED AT: 2020

G #ASCO20 Slides are the property of the author, permission required for reuse.

PRESENTED BY:

4 6



- Randomization is stratified by study site, and diagnosis (newly diagnosed vs. relapsed/refractory)
- Sites: MGH, Duke, Penn, Ohio State



# Patient Eligibility Criteria

- Hospitalized patients (age > 18) with high-risk AML receiving intensive chemotherapy
- Exclusion criteria:
  - Patients with APML
  - Patients receiving non-intensive chemotherapy
  - Patients already receiving palliative care
  - Patients with major psychiatric or comorbid conditions



#### High-risk AML

- 1) Newly diagnosed  $\geq$  60 years
- 2) Antecedent hematologic disorder or therapy related
- 3) Relapsed or primary refractory AML

Areej El-Jawahri MD

PRESENTED AT: 2020

G #ASCO20 Slides are the property of the author, permission required for reuse.





### **Study Measures**

- Patient-reported outcomes measured at baseline, weeks 2, 4, 12, and 24
- Primary endpoint: QOL (FACT-Leukemia) at week-2
- Secondary endpoints:
  - Psychological distress (HADS and PHQ-9)
  - Symptom burden (ESAS)
  - PTSD symptoms (PTSD Checklist- Civilian Version)
  - $\circ$  EOL outcomes:
    - Patient-reported discussions of EOL care wishes
    - Hospitalizations in the last week of life
    - Chemotherapy administration in the last 30 days of life
    - Hospice utilization

Areej El-Jawahri MD



PRESENTED AT: 2020

G #ASCO20 Slides are the property of the author, permission required for reuse.





• ANCOVA to assess the impact of the intervention on patient-reported outcomes at week-2 adjusting for baseline scores.

PRESENTED BY:

- Mixed linear effect models using Maximum Likelihood to account for missing data to examine the effect of the intervention on patient-reported outcomes longitudinally across all time points (baseline, weeks 2, 4, 12, and 24).
- Fisher's exact test for dichotomous EOL outcomes.


#ASCO20

are the property of the author

2020

PRESENTED AT:

Areej El-Jawahri MD



Areej El-Jawahri MD

5 1

PRESENTED AT: 2020ASCO ANNUAL MEETING

\* #ASCO20 Slides are the property of the author, permission required for reuse.





#### **Baseline Demographics**

Patient Characteristics	Usual Care (N = 74)	Integrated Palliative and Oncology Care (N = 86)
Age, median (range)	65.2 (22.1-80.1)	63.0 (19.7-77.8)
Female sex, n (%)	27 (36.5%)	37 (43.0%)
Race, n (%) White Black American Indian Asian Other	63 (85.1%) 7 (9.5%) 2 (2.7%) 2 (2.7%) 0	75 (87.2%) 8 (9.4%) 2 (2.3%) 0 1 (1.2%)
Hispanic, n (%)	0 (0.0%)	5 (6.02%)
Diagnosis type, n (%) Newly diagnosed AML Relapsed AML Refractory AML	50 (67.6%) 16 (21.6%) 8 (10.8%)	59 (68.6%) 21 (24.4%) 6 (7.0%)

Areej El-Jawahri MD

5 2




#ASCO20 Slides are the property of the author, permission required for reuse.





#### **Palliative Care Intervention Focus During Intensive Chemotherapy Hospitalization**



Areej El-Jawahri MD

2020ASCO PRESENTED AT: ANNUAL MEETING

#ASCO20 Slides are the property of the author, permission required for reuse.

# MGH **Symptoms Addressed During Palliative Care Visits**


2020ASCO

ANNUAL MEETING

PRESENTED AT:

#ASCO20


permission required for reuse.



Areej El-Jawahri MD



# Palliative Care Intervention Focus During Subsequent Hospitalizations




Areej El-Jawahri MD

5 5

PRESENTED AT: 2020ASCO ANNUAL MEETING

#ASCO20 Slides are the property of the author, permission required for reuse.





Areej El-Jawahri MD


5 6

PRESENTED AT: 2020ASCO ANNUAL MEETING

#ASCO20 Slides are the property of the permission required for reuse.







QOL

**Group # Time B =** 2.35

95% CI 0.02–4.68, **P** = **0.048** 

Areej El-Jawahri MD



PRESENTED AT: 2020 ASCO ANNUAL MEETING


#ASCO20 Slides are the property of the author, permission required for reuse.





**Anxiety symptoms** 

**Group # Time B** = -0.38 95% CI -0.75 - -0.01, **P = 0.042** 




Areej El-Jawahri MD

PRESENTED AT: 2020ASCO ANNUAL MEETING

#ASCO20 Slides are the property of the author, permission required for reuse.







**Depression symptoms** 

**Group # Time B** = -0.42 95% Cl -0.82 - -0.02, **P** = 0.039

Areej El-Jawahri MD

PRESENTED AT: 2020 ASCO ANNUAL MEETING

#ASCO20 Slides are the property of the author, permission required for reuse.





**Depression syndrome** 

PRESENTED AT:


**Group # Time B** = -0.21 95% Cl -0.67 – 0.25, P = 0.375

2020**ASCO** 

ANNUAL MEETING

#ASCO20

Slides are the property of the author, permission required for reuse.



Areej El-Jawahri MD





Seline Week2 Week4 Week12 Week24 Usual Care Intervention

Symptom burden

**Group # Time** B = -0.38 95% Cl -2.09 – 1.32, P = 0.659

Areej El-Jawahri MD



PRESENTED AT: 2020 ASCO ANNUAL MEETING

#ASCO20 Slides are the property of the author, permission required for reuse.






PTSD symptoms

PRESENTED AT:

**Group # Time B** = -1.43 95% Cl -2.34 - -0.54, **P** = 0.002



Areej El-Jawahri MD


2020 ASCO ANNUAL MEETING

#ASCO20 Slides are the property of the author, permission required for reuse.






# Patient-reported discussions of EOL care wishes



#### Receipt of chemotherapy in the last 30 days of life



\* 87 participants were deceased at 6-month follow up

\* No difference in hospitalizations at the EOL or hospice utilization

Areej El-Jawahri MD

6 3

PRESENTED AT: 2020ASCO ANNUAL MEETING

\* #ASCO20 Slides are the property of the author, permission required for reuse.





- Integrated palliative and oncology care improves QOL, depression and anxiety symptoms, as well as post-traumatic stress symptoms for patients with AML.
- The palliative care intervention led to sustained improvements in QOL and psychological distress six months after initiating chemotherapy in patients with AML.
- Patients receiving the intervention were more likely to discuss their EOL care preferences with their clinicians and less likely to use chemotherapy in the last month of life.

PRESENTED BY:

#ASCO20

are the property of the author

2020

PRESENTED AT:

Areej El-Jawahri MD

### Conclusions

Palliative care improves outcomes in hematology too, but we need more evidence

- Novel intervention development, testing
- Other diseases

Need for clinician education, behavior change

...and primary palliative care skill development

Care model challenges remain; need for policy change

- Transfusions, chemotherapy and hospice

Implementation and dissemination is the next big challenge to overcome!



# **QUESTIONS AND DISCUSSION**